Results for tag: "Pelitinib"

Pelitinib is an oncology drug used to treat certain types of cancer, such as non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Pelitinib is approved for use in combination with chemotherapy for the treatment of metastatic NSCLC in patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It is also approved for use as a monotherapy for the treatment of metastatic NSCLC in patients with EGFR exon 20 insertion mutations. Pelitinib is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for the treatment of other types of cancer, such as breast cancer and colorectal cancer. The market for Pelitinib is highly competitive, with several companies developing and marketing the drug. These include AstraZeneca, Daiichi Sankyo, and Eli Lilly. Show Less Read more